The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus.
about
Sitagliptin/metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapyDipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studiesSafety and efficacy of sitagliptin-metformin in fixed combination for the treatment of type 2 diabetes mellitusCardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-AnalysisUnderstanding and overcoming metformin gastrointestinal intolerance.Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparisonGlycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.Impact of three oral antidiabetic drugs on markers of β-cell function in patients with type 2 diabetes: a meta-analysis.Efficacy and safety of linagliptin co-administered with low-dose metformin once daily versus high-dose metformin twice daily in treatment-naïve patients with type 2 diabetes: a double-blind randomized trial.Microflora Disturbance during Progression of Glucose Intolerance and Effect of Sitagliptin: An Animal StudyEffects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials.Sitagliptin/Metformin (janumet) as combination therapy in the treatment of type-2 diabetes mellitusCardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis.Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin.Initial combination therapy for patients with type 2 diabetes mellitus: considerations for metformin plus linagliptin.Drug-induced hypoglycaemia in type 2 diabetes.Combine and conquer: advantages and disadvantages of fixed-dose combination therapy.Use of the dipeptidyl peptidase-4 inhibitor linagliptin in combination therapy for type 2 diabetes.Initial combination with linagliptin and metformin in newly diagnosed type 2 diabetes and severe hyperglycemia.Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis.Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.Incretin-based therapies: focus on effects beyond glycemic control alone.Sitagliptin: a review of its use in patients with type 2 diabetes mellitus.Real-world effectiveness of sitagliptin as add-on therapy in patients with type 2 diabetes mellitus.Implications of incretin-based therapies on cardiovascular disease.Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study).The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too" or "the Special One" Antidiabetic Class?Early Combination Therapy with Oral Glucose-Lowering Agents in Type 2 Diabetes.Recent development of single preparations and fixed-dose combination tablets for the treatment of non-insulin-dependent diabetes mellitus : A comprehensive summary for antidiabetic drugs.The power of two: an update on fixed-dose combinations for type 2 diabetes.Adverse effects of incretin-based therapies on major cardiovascular and arrhythmia events: meta-analysis of randomized trials.Effect of addition of either sitagliptin or pioglitazone in patients with uncontrolled type 2 diabetes mellitus on metformin: A randomized controlled trialEfficacy and safety of sitagliptin/metformin fixed-dose combination compared with glimepiride in patients with type 2 diabetes: A multicenter randomized double-blind study.Efficacy, safety and impact on β-cell function of dipeptidyl peptidase-4 inhibitors plus metformin combination therapy in patients with type 2 diabetes and the difference between Asians and Caucasians: a meta-analysis.A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus.Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies.Safety of sitagliptin in elderly patients with type 2 diabetes: a pooled analysis of 25 clinical studies.Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial.Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis.A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control.
P2860
Q26739888-05D4A894-C242-4A4B-96A9-39723047F7DEQ26765047-0E07F4AB-3AD7-4E73-949B-8A7DA40D84B0Q27027877-A9970557-2184-40B7-A302-88A90A953E91Q28071764-60F1E0AF-22EE-43D3-BD36-4F4BB977BDB5Q30240030-4C381E6D-F0C2-40F2-98B7-3B198CDDAB87Q33785197-080E8F36-D597-4DC5-B11F-31104BC56902Q34265490-AA1D82F3-0F57-4FE6-A9DE-CC3DE0F13D2AQ35034772-DC653F4F-4C8E-4505-84C8-0876BD929662Q35225426-7C7F409E-1C40-4DD9-B92D-45E7DDE8CDC2Q36133669-52A3A4B4-72FE-4F1A-92A1-F275576814F8Q36315963-49ECBDDE-5EC0-4505-96BC-7E61FF006A14Q36523423-F2404CD9-08ED-4715-9576-ADEC9D12FBBCQ36649277-0E6F80E0-E699-429E-82B7-BE8941B6D4D8Q36906018-96B3251A-2C37-4E3D-A3CF-E7B727781675Q37449243-9D1D4558-BDD0-4E36-A694-090AAFEB4C51Q38018110-70DBBE10-D35B-4FB4-B2FB-6A49586BFEA5Q38046641-4A0CDBFA-C9BB-487B-BD25-989B4A0CB432Q38058568-4B9E0CF5-8F00-42BA-BC55-DFE592C16470Q38065105-3EED4F0D-6BDC-4D5A-8233-7345AD38F27EQ38076330-B84E7C6F-7E31-4460-B152-E3C4948B653AQ38106411-90683A50-1312-425C-A9ED-39B94F35432CQ38140803-AB0EF62B-8946-43DB-B4C0-D611E89D72CFQ38177173-5C0F8A53-6DED-4234-8928-769D5933C390Q38219491-0EF2913E-DCCB-444F-B2E9-678FCC9E649FQ38264374-D30D4F5D-1878-4C8F-AD78-6BA3C210D480Q38410754-E9900937-8E9D-437C-84AE-C2416F51FC9EQ38527885-DE384890-1D40-44A2-9C0D-6FC7E3AB51A1Q38762377-C9228D95-A9D0-4F10-A645-DE522FAEB583Q38845574-D269382D-311B-49E3-BC72-1BAD502CDE7DQ38920983-C52C20F0-8394-48C5-8B63-F5BDE2E0C746Q39870068-55708F60-F399-4C4F-973F-6767F8727297Q40358908-86A33D71-9802-469E-9873-24570DD198ECQ40492085-DCB0F0E5-ACA0-447D-9F79-B1502E7409FAQ40803621-AF09B4C0-7BA8-412C-B484-FA6A558CD929Q41477500-9D60F08C-A801-44B6-BB2C-DE52B949F522Q41966262-12C9D27F-2293-4CD2-9ADF-C0330FE5D870Q44548336-34DE6CD4-2241-4F10-8170-5166AC238337Q46595958-99ADDB90-2DDD-4090-93A8-621F8F5E8834Q50876480-61EEF17C-48AA-40E6-B067-7BEBF076EAFEQ51293354-379FA925-7B3D-492D-A8A3-7C749E5CDCC0
P2860
The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
The effect of initial therapy ...... with type 2 diabetes mellitus.
@en
The effect of initial therapy ...... with type 2 diabetes mellitus.
@nl
type
label
The effect of initial therapy ...... with type 2 diabetes mellitus.
@en
The effect of initial therapy ...... with type 2 diabetes mellitus.
@nl
prefLabel
The effect of initial therapy ...... with type 2 diabetes mellitus.
@en
The effect of initial therapy ...... with type 2 diabetes mellitus.
@nl
P2093
P2860
P1476
The effect of initial therapy ...... with type 2 diabetes mellitus.
@en
P2093
A O Johnson-Levonas
B J Goldstein
D E Williams-Herman
K D Kaufman
L Terranella
P2860
P304
P356
10.1111/J.1463-1326.2011.01390.X
P577
2011-07-01T00:00:00Z